Partial
Partially Aligned
Patient Risk:
Low
Summary
The evaluation generally identifies what the supplied label supports or does not address, but it introduces cough-rate figures not present in the supplied label and treats selected-patient trial rates as sufficient to contradict general-population incidence claims.
Category Scores
Accurate Statements
The label reports cough rates of 17% and 29% with losartan in trials enrolling patients with prior ACE-inhibitor-associated cough, and 62% and 69% with lisinopril.
Section 6.1 reports these rates in two trials specifically enrolling patients whose cough occurred with ACE-inhibitor therapy.
The label reports losartan-associated cough cases, including positive rechallenges, but does not provide a reliable postmarketing frequency estimate.
Section 6.1 reports cough cases, including positive rechallenges. Section 6.2 explains that voluntary postmarketing reports from a population of uncertain size do not permit reliable frequency estimation.
The label does not substantiate the listed switching advice, alternative-drug lists, or cough-resolution timelines.
The supplied sections do not address these recommendations or timelines.
Unsupported Statements
The label reports cough in 3.1% of losartan-treated patients in controlled trials, versus 2.6% with placebo.
These figures do not appear in the supplied prescribing-information sections.
The classifications of general under-1% cough-incidence claims as contradicted are reasonable based on the 17% and 29% losartan rates.
Those rates are from a selected population with prior ACE-inhibitor cough and do not establish general-population incidence. The supplied label does not provide a general-population losartan cough rate that directly contradicts an under-1% claim.
Contradictions
Important Omissions
The evaluation should consistently distinguish the selected trial population with prior ACE-inhibitor cough from typical losartan users, and should not use those selected-population rates alone to classify general-incidence claims as contradicted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The material is an evaluation of cough claims rather than direct dosing or treatment advice. Its main issue is overstating what the supplied label establishes about general cough incidence.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
The response cites cough rates absent from the supplied label and overgeneralizes rates from a population selected for prior ACE-inhibitor cough.
Suggested Improvement
Remove the unsupported 3.1% and 2.6% figures. State that the supplied label reports 17% and 29% rates only in the selected prior-ACE-inhibitor-cough trials and does not establish a general-population incidence.